Japan's Eisai, Takeda And Shionogi Look To Accelerate Weight Loss Drug Development
This article was originally published in PharmAsia News
Executive Summary
Major Japanese drug companies Eisai and Takeda are looking to accelerate commercialization of weight loss drugs for metabolic syndrome. Eisai's anti-obesity agent KES524 (sibutramine), licensed from Abbott Laboratories, is pending approval in Japan. Takeda's therapeutic diet agent ATL-962 (cetilistat) is in Phase III clinical development in Japan. Takeda obtained the exclusive rights from U.K. biotech Alizyme. Shionogi also plans a Phase I trial for S-2367 by the end of this September. S-2367 is at Phase II development in the U.S. Other Japanese drug makers are developing over-the-counter obesity drugs. Taisho Pharmaceutical obtained exclusive rights to Alli (oristat) from GlaxoSmithKline in January. Kobayashi Pharmaceutical launched traditional Chinese medicine Beslight Gold a targeting middle-aged females and Naisitoru85 targeting male customers. Marketing firm Fuji Keizai estimated a 4 percent increase to ¥12 billion for the obesity drug market in 2009. (Click here for more - Japanese language
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.